147 related articles for article (PubMed ID: 24706357)
21. Clonal expansion and epigenetic reprogramming following deletion or amplification of mutant
Mazor T; Chesnelong C; Pankov A; Jalbert LE; Hong C; Hayes J; Smirnov IV; Marshall R; Souza CF; Shen Y; Viswanath P; Noushmehr H; Ronen SM; Jones SJM; Marra MA; Cairncross JG; Perry A; Nelson SJ; Chang SM; Bollen AW; Molinaro AM; Bengtsson H; Olshen AB; Weiss S; Phillips JJ; Luchman HA; Costello JF
Proc Natl Acad Sci U S A; 2017 Oct; 114(40):10743-10748. PubMed ID: 28916733
[No Abstract] [Full Text] [Related]
22. Characterizing temporal genomic heterogeneity in pediatric low-grade gliomas.
Lazow MA; Hoffman L; Schafer A; Osorio DS; Boué DR; Rush S; Wright E; Lane A; DeWire-Schottmiller MD; Smolarek T; Sipple J; Taggert H; Reuss J; Salloum R; Hummel TR; de Blank P; Pillay-Smiley N; Sutton ME; Asher A; Stevenson CB; Drissi R; Finlay JL; Fouladi M; Fuller C
Acta Neuropathol Commun; 2020 Nov; 8(1):182. PubMed ID: 33153497
[TBL] [Abstract][Full Text] [Related]
23. Genomic characterization of recurrent high-grade astroblastoma.
Bale TA; Abedalthagafi M; Bi WL; Kang YJ; Merrill P; Dunn IF; Dubuc A; Charbonneau SK; Brown L; Ligon AH; Ramkissoon SH; Ligon KL
Cancer Genet; 2016; 209(7-8):321-30. PubMed ID: 27425854
[TBL] [Abstract][Full Text] [Related]
24. Whole-genome and multisector exome sequencing of primary and post-treatment glioblastoma reveals patterns of tumor evolution.
Kim H; Zheng S; Amini SS; Virk SM; Mikkelsen T; Brat DJ; Grimsby J; Sougnez C; Muller F; Hu J; Sloan AE; Cohen ML; Van Meir EG; Scarpace L; Laird PW; Weinstein JN; Lander ES; Gabriel S; Getz G; Meyerson M; Chin L; Barnholtz-Sloan JS; Verhaak RG
Genome Res; 2015 Mar; 25(3):316-27. PubMed ID: 25650244
[TBL] [Abstract][Full Text] [Related]
25. Characterizing temporal genomic heterogeneity in pediatric high-grade gliomas.
Salloum R; McConechy MK; Mikael LG; Fuller C; Drissi R; DeWire M; Nikbakht H; De Jay N; Yang X; Boue D; Chow LML; Finlay JL; Gayden T; Karamchandani J; Hummel TR; Olshefski R; Osorio DS; Stevenson C; Kleinman CL; Majewski J; Fouladi M; Jabado N
Acta Neuropathol Commun; 2017 Oct; 5(1):78. PubMed ID: 29084603
[TBL] [Abstract][Full Text] [Related]
26. ATRX and IDH1-R132H immunohistochemistry with subsequent copy number analysis and IDH sequencing as a basis for an "integrated" diagnostic approach for adult astrocytoma, oligodendroglioma and glioblastoma.
Reuss DE; Sahm F; Schrimpf D; Wiestler B; Capper D; Koelsche C; Schweizer L; Korshunov A; Jones DT; Hovestadt V; Mittelbronn M; Schittenhelm J; Herold-Mende C; Unterberg A; Platten M; Weller M; Wick W; Pfister SM; von Deimling A
Acta Neuropathol; 2015 Jan; 129(1):133-46. PubMed ID: 25427834
[TBL] [Abstract][Full Text] [Related]
27. Clonal evolution of glioblastoma under therapy.
Wang J; Cazzato E; Ladewig E; Frattini V; Rosenbloom DI; Zairis S; Abate F; Liu Z; Elliott O; Shin YJ; Lee JK; Lee IH; Park WY; Eoli M; Blumberg AJ; Lasorella A; Nam DH; Finocchiaro G; Iavarone A; Rabadan R
Nat Genet; 2016 Jul; 48(7):768-76. PubMed ID: 27270107
[TBL] [Abstract][Full Text] [Related]
28. Genomic analysis reveals secondary glioblastoma after radiotherapy in a subset of recurrent medulloblastomas.
Phi JH; Park AK; Lee S; Choi SA; Baek IP; Kim P; Kim EH; Park HC; Kim BC; Bhak J; Park SH; Lee JY; Wang KC; Kim DS; Shim KW; Kim SH; Kim CY; Kim SK
Acta Neuropathol; 2018 Jun; 135(6):939-953. PubMed ID: 29644394
[TBL] [Abstract][Full Text] [Related]
29. Ivosidenib, an IDH1 inhibitor, in a patient with recurrent,
Tejera D; Kushnirsky M; Gultekin SH; Lu M; Steelman L; de la Fuente MI
CNS Oncol; 2020 Sep; 9(3):CNS62. PubMed ID: 32716208
[TBL] [Abstract][Full Text] [Related]
30. Detrended fluctuation analysis of genome-wide copy number profiles of glioblastomas using array-based comparative genomic hybridization.
Nakahara Y; Shiraishi T; Okamoto H; Mineta T; Oishi T; Sasaki K; Tabuchi K
Neuro Oncol; 2004 Oct; 6(4):281-9. PubMed ID: 15494095
[TBL] [Abstract][Full Text] [Related]
31. Chromosomal aberrations detected by comparative genomic hybridization (CGH) in human astrocytic tumors.
Maruno M; Yoshimine T; Muhammad AK; Ninomiya H; Kato A; Hayakawa T
Cancer Lett; 1999 Jan; 135(1):61-6. PubMed ID: 10077222
[TBL] [Abstract][Full Text] [Related]
32. Targeted Genomic Sequencing Reveals Different Evolutionary Patterns Between Locally and Distally Recurrent Glioblastomas.
Yoon N; Kim HS; Lee JW; Lee EJ; Maeng LS; Yoon WS
Cancer Genomics Proteomics; 2020; 17(6):803-812. PubMed ID: 33099481
[TBL] [Abstract][Full Text] [Related]
33. Patients with IDH1 wild type anaplastic astrocytomas exhibit worse prognosis than IDH1-mutated glioblastomas, and IDH1 mutation status accounts for the unfavorable prognostic effect of higher age: implications for classification of gliomas.
Hartmann C; Hentschel B; Wick W; Capper D; Felsberg J; Simon M; Westphal M; Schackert G; Meyermann R; Pietsch T; Reifenberger G; Weller M; Loeffler M; von Deimling A
Acta Neuropathol; 2010 Dec; 120(6):707-18. PubMed ID: 21088844
[TBL] [Abstract][Full Text] [Related]
34. Increased sensitivity to radiochemotherapy in IDH1 mutant glioblastoma as demonstrated by serial quantitative MR volumetry.
Tran AN; Lai A; Li S; Pope WB; Teixeira S; Harris RJ; Woodworth DC; Nghiemphu PL; Cloughesy TF; Ellingson BM
Neuro Oncol; 2014 Mar; 16(3):414-20. PubMed ID: 24305712
[TBL] [Abstract][Full Text] [Related]
35. Molecular differences in IDH wildtype glioblastoma according to MGMT promoter methylation.
Kessler T; Sahm F; Sadik A; Stichel D; Hertenstein A; Reifenberger G; Zacher A; Sabel M; Tabatabai G; Steinbach J; Sure U; Krex D; Grosu AL; Bewerunge-Hudler M; Jones D; Pfister SM; Weller M; Opitz C; Bendszus M; von Deimling A; Platten M; Wick W
Neuro Oncol; 2018 Feb; 20(3):367-379. PubMed ID: 29016808
[TBL] [Abstract][Full Text] [Related]
36. Spatial transcriptome analysis reveals Notch pathway-associated prognostic markers in IDH1 wild-type glioblastoma involving the subventricular zone.
Jungk C; Mock A; Exner J; Geisenberger C; Warta R; Capper D; Abdollahi A; Friauf S; Lahrmann B; Grabe N; Beckhove P; von Deimling A; Unterberg A; Herold-Mende C
BMC Med; 2016 Oct; 14(1):170. PubMed ID: 27782828
[TBL] [Abstract][Full Text] [Related]
37. Glioblastomas with IDH1/2 mutations have a short clinical history and have a favorable clinical outcome.
Ohno M; Narita Y; Miyakita Y; Matsushita Y; Arita H; Yonezawa M; Yoshida A; Fukushima S; Takami H; Ichimura K; Shibui S
Jpn J Clin Oncol; 2016 Jan; 46(1):31-9. PubMed ID: 26603354
[TBL] [Abstract][Full Text] [Related]
38. Genomic aberrations frequently alter chromatin regulatory genes in chordoma.
Wang L; Zehir A; Nafa K; Zhou N; Berger MF; Casanova J; Sadowska J; Lu C; Allis CD; Gounder M; Chandhanayingyong C; Ladanyi M; Boland PJ; Hameed M
Genes Chromosomes Cancer; 2016 Jul; 55(7):591-600. PubMed ID: 27072194
[TBL] [Abstract][Full Text] [Related]
39. Genome-wide molecular characterization of central nervous system primitive neuroectodermal tumor and pineoblastoma.
Miller S; Rogers HA; Lyon P; Rand V; Adamowicz-Brice M; Clifford SC; Hayden JT; Dyer S; Pfister S; Korshunov A; Brundler MA; Lowe J; Coyle B; Grundy RG
Neuro Oncol; 2011 Aug; 13(8):866-79. PubMed ID: 21798848
[TBL] [Abstract][Full Text] [Related]
40. Wild‑type IDH1 affects cell migration by modulating the PI3K/AKT/mTOR pathway in primary glioblastoma cells.
Shen X; Wu S; Zhang J; Li M; Xu F; Wang A; Lei Y; Zhu G
Mol Med Rep; 2020 Sep; 22(3):1949-1957. PubMed ID: 32705169
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
